The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
14 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $73,482,326 in first-year total cost, median $5,845,237.
Most frequent study sections
- Special Emphasis Panel[ZAI1 LG-M (J1)]9
- Special Emphasis Panel[ZAI1 LG-M (J2)]4
- ZAI1-SRC(99)1
Most frequent institutions
- ALBERT EINSTEIN COLLEGE OF MEDICINE1
- BROAD INSTITUTE, INC.1
- GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT1
- HACKENSACK UNIVERSITY MEDICAL CENTER1
- HARVARD MEDICAL SCHOOL1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2019 | Antiviral Drug Discovery and Development Center (AD3C)1U19AI142759-01 | WHITLEY, RICHARD J. | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $7,500,000 | ZAI1 |
| 2019 | Autophagy Modulators as Novel Broad-Spectrum Anti-Infective Agents1U19AI142784-01 | LEVINE, BETH C | UT SOUTHWESTERN MEDICAL CENTER, TX | $7,381,267 | ZAI1 |
| 2019 | Consortium for Immunotherapeutics against Emerging Viral Threats1U19AI142790-01 | SAPHIRE, ERICA OLLMANN | LA JOLLA INSTITUTE FOR IMMUNOLOGY, CA | $7,168,390 | ZAI1 |
| 2019 | Innovative technologies to transform antibiotic discovery.1U19AI142780-01 | HUNG, DEBORAH T | BROAD INSTITUTE, INC., MA | $7,082,911 | ZAI1 |
| 2019 | Advancement of Vaccines and Treatments for Ebola and Marburg Virus Infections1U19AI142785-01 | GEISBERT, THOMAS WILLIAM | UNIVERSITY OF TEXAS MED BR GALVESTON, TX | $7,043,167 | ZAI1 |
| 2019 | Center to develop innovative therapeutics to multidrug resistant high-threat bacterial agents1U19AI142731-01 | PERLIN, DAVID S | HACKENSACK UNIVERSITY MEDICAL CENTER, NJ | $6,880,060 | ZAI1 |
| 2019 | Novel antimicrobials targeting MDR pathogens from animal microbial symbionts1U19AI142720-01 | ANDES, DAVID R | UNIVERSITY OF WISCONSIN-MADISON, WI | $6,205,014 | ZAI1 |
| 2019 | Modulation of Protein production and Degradation as an integrated approach to rapid sterilization of Drug sensitive and resistant Mtb.1U19AI142735-01 | FOTOUHI, NADER | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, NY | $5,485,460 | ZAI1 |
| 2019 | Prometheus: A Platform for Rapid Development of Human Antibody-based Therapeutics and Prophylactics against Emerging Viral Threats1U19AI142777-01 | CHANDRAN, KARTIK | ALBERT EINSTEIN COLLEGE OF MEDICINE, NY | $4,348,829 | ZAI1 |
| 2019 | Advancement of Vaccines and Therapies for Henipaviruses1U19AI142764-01 | BRODER, CHRISTOPHER C | HENRY M. JACKSON FDN FOR THE ADV MIL/MED, MD | $4,260,825 | ZAI1 |
| 2019 | Center of Excellence for Encephalitic Alphavirus Therapeutics1U19AI142762-01 | JONSSON, COLLEEN B | UNIVERSITY OF TENNESSEE HEALTH SCI CTR, TN | $3,723,013 | ZAI1 |
| 2019 | Bacterial Determinants of Treatment Response in Mycobacteria Tuberculosis1U19AI142793-01 | MURRAY, MEGAN B | HARVARD MEDICAL SCHOOL, MA | $2,903,390 | ZAI1 |
| 2019 | Active Vaccination and Passive Antibody Strategies to Prevent Disease Caused by Multidrug-Resistant Bacterial Pathogens1U19AI142725-01 | LEVINE, MYRON MAX | UNIVERSITY OF MARYLAND BALTIMORE, MD | $2,500,000 | ZAI1 |
| 2019 | Respiratory Virus Vaccine and Adjuvant Exploration1U01AI149644-01 | BARIC, RALPH S | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $1,000,000 | ZAI1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.